Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
October 12, 2016
– Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis…
Read morepress release
August 10, 2016
Geneva, Switzerland, 10 August 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…
Read morepress release
July 28, 2016
Geneva, Switzerland, 28 July 2016 – ObsEva, a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to…
Read moreMay 28, 2021
June 9, 2020
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840